Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Upgrades PPL to Buy with 30 Price Target

Elaine Mendonca by Elaine Mendonca
March 8, 2024
in Breaking News
0
Finance_Assets
0
SHARES
3
VIEWS
Share on FacebookShare on Twitter

Analyst Jacob Kilstein from Argus Research has recently raised his rating on PPL (NYSE:PPL) from Hold to Buy, with a price target of $30. This upgrade reflects optimism about the company’s potential for growth, signaling a bright future ahead for PPL.

March 8, 2024

PPL Corporation Stock Price Sees Positive Momentum on March 8, 2024

On March 8, 2024, PPL Corporation (PPL) experienced a slight increase in its stock price, continuing its positive momentum in the market. According to data from CNN Money, PPL is currently trading in the middle of its 52-week range and above its 200-day simple moving average, indicating a stable position in the market.

As of the market close on March 7, 2024, PPL shares were priced at $26.88. The stock price saw a modest increase of $0.03, representing a 0.11% rise since the previous trading day. This uptick in price reflects a positive sentiment among investors towards the company.

Furthermore, in pre-market trading on March 8, PPL stock continued to climb, with a further increase of $0.24. This additional gain suggests that investors are optimistic about the company’s future performance and are willing to pay a higher price for its shares.

Overall, PPL’s stock performance on March 8, 2024, demonstrates a positive trend, with the stock price showing resilience and upward momentum. Investors may be encouraged by the company’s financial health and growth prospects, leading to increased demand for PPL shares in the market.

PPL Corporation (PPL) Stock Performance Analysis: Revenue and Net Income Up, EPS Down – March 8, 2024

On March 8, 2024, PPL Corporation (PPL) saw some interesting stock performances based on the financial data provided by CNN Money. Total revenue for PPL stood at $8.31 billion for the past year, showing a 5.19% increase compared to the previous year. Net income for PPL was reported at $739 million for the past year, reflecting a 3.65% increase from the previous year. Earnings per share (EPS) for PPL stood at $1.00 for the past year, showing a 3.46% increase compared to the previous year. Overall, PPL’s stock performances on March 8, 2024, show a mixed bag of results. While the company has seen growth in total revenue, net income, and EPS over the past year, there has been no significant improvement in the most recent quarter. The decrease in EPS for the last quarter could be a red flag for investors, and it will be important to monitor the company’s financial performance closely in the coming quarters.

Tags: PPL
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Finances

Analyst Jason Helfstein Downgrades FIGS Rating from Outperform to Perform

DrugRetailers Trading online

Analysts Raise Price Targets for Burlington Stores After Strong Q4 Results

Neptune Wellness Solutions Announces Major Leadership Changes

Recommended

Super Micro Computer Stock

Super Micro Stock Surges Amid AI Infrastructure Boom

4 months ago
Adobe Stock

Adobe’s AI Ambitions Face Investor Skepticism

4 months ago
IBM Stock

Strong IBM Earnings Fail to Impress Market as Key Segment Shows Weakness

4 months ago
Inozyme Pharma Inc Stock

Inozyme Pharma Acquisition Finalized: Strategic Focus Shifts to Clinical Development

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Myers Industries Set to Report Full-Year and Q4 2025 Results

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

Riley Exploration Permian Bolsters Board with Industry Veteran Amid Shareholder Activity

Great Lakes Dredge & Dock: A Cash Flow Inflection Point Approaches

Investors Await March Report for Boston Omaha’s Strategic Direction

Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds

Trending

Orthofix Medical Stock
Earnings

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

by Rodolfo Hanigan
February 7, 2026
0

Investor attention turns to Orthofix Medical as the company bolsters the clinical support for its biologics business...

CrossFirst Bankshares Stock

A New Chapter for First Busey as CrossFirst Merger Finalizes

February 7, 2026
Golden Entertainment Stock

Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

February 7, 2026
Myers Industries Stock

Myers Industries Set to Report Full-Year and Q4 2025 Results

February 7, 2026
OneSpan Stock

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio
  • A New Chapter for First Busey as CrossFirst Merger Finalizes
  • Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com